Clinical Trials · NCT01146678

Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1

Name: Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 1Lixisenatide

Phase: Phase 1
Recruitment status: Completed
Sponsor: Sanofi
Enrollment: 22
Start date: Jun 2010
Locations: 1 site, Germany
Primary endpoint: Area under the plasma lixisenatide concentration curve (LIX-AUClast)

View Lixisenatide compound reference